Circulating biomarkers—including conventional serologic markers (LDH, S100B), circulating tumor DNA (ctDNA), and small non-coding RNAs such as microRNAs (miRNAs)—offer complementary information that can anticipate therapeutic efficacy or resistance long before radiologic evidence becomes apparent. This evidence concerns the gene S100B and neoplasm.